A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00543920
Recruitment Status : Completed
First Posted : October 15, 2007
Last Update Posted : November 26, 2015
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:

The study will look at the effect of MK0777on reducing anxiety in subjects with general anxiety disorder.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Condition or disease Intervention/treatment Phase
Anxiety Disorders Drug: MK0777 Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Study Start Date : August 2002
Primary Completion Date : February 2003
Study Completion Date : February 2003

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anxiety
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of General Anxiety Order

Exclusion Criteria:

  • Women who are pregnant or breast-feeding
  • History of severe drug reaction
  • History of severe drug withdrawal symptoms such as seizures or delirium
  • Disease of cardiovascular system
  • Disease of the liver, kidneys, endocrine system, metabolic system or eyes
  • History of seizures or seizure disorder
  • History of drug or alcohol abuse

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00543920

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Medical Monitor Merck Sharp & Dohme Corp.

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00543920     History of Changes
Other Study ID Numbers: 0777-020
First Posted: October 15, 2007    Key Record Dates
Last Update Posted: November 26, 2015
Last Verified: November 2015

Additional relevant MeSH terms:
Anxiety Disorders
Mental Disorders